SynthesisFrontiers in pharmacology2026
Comparative efficacy and safety of Xuesaitong injection as adjuvant therapy for acute pancreatitis: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Xuesaitong injection has been explored as an off-label adjuvant therapy for acute pancreatitis in China, but its efficacy and safety remain uncertain. This systematic review and meta-analysis evaluated Xuesaitong injection combined with conventional therapy for acute pancreatitis. Methods: Randomized controlled trials of Xuesaitong injection for acute pancreatitis were searched in the Cochrane Library, Embase, Web of Science, PubMed, China National Knowledge Infrastructure, Wanfang Database, VIP Database, and Chinese Biomedical Literature Database from inception to 1 March 2026. Two reviewers independently performed study screening, data extraction, and risk-of-bias assessment. Meta-analysis was conducted using a random-effects model, and certainty of evidence was assessed using the Grading of Recommendations Assessment, Development and Evaluation approach. Results: Sixteen randomized controlled trials involving 1,529 patients were included. Compared with conventional therapy alone, Xuesaitong injection plus conventional therapy improved the clinical response rate (relative risk = 1.15, 95% confidence interval 1.11-1.20), shortened length of hospital stay (mean difference = -5.18 days, 95% confidence interval -6.73 to -3.63), and reduced Acute Physiology and Chronic Health Evaluation II scores (mean difference = -1.99 points, 95% confidence interval -3.54 to -0.43). It also reduced inflammatory markers and amylase levels, including tumor necrosis factor-alpha, C-reactive protein, interleukin-6, interleukin-2, soluble intercellular adhesion molecule-1, serum amylase, and urinary amylase. The incidence of reported safety-related events was 6.43% in the experimental group and 7.04% in the control group. No serious adverse events clearly attributed to Xuesaitong injection were reported. Six studies had a high risk of bias, and the certainty of evidence was low or very low. Conclusion: Xuesaitong injection may provide additional benefits as adjuvant therapy for acute pancreatitis. However, methodological limitations, substantial heterogeneity, possible publication bias, and insufficient safety reporting warrant cautious interpretation. High-quality multicenter randomized controlled trials are needed. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261335764, identifier CRD420261335764.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.